Infectious Disease AdvisorTrump Ends Push to Slash Prescription Drug Costs

President Trump’s recent executive order eliminates several Biden administration healthcare initiatives, particularly those focused on prescription drug costs and healthcare access. Although maintaining key provisions of the Inflation Reduction Act, including Medicare drug price negotiations, the order removes policies aimed at expanding Medicare and Medicaid coverage and accessibility.

Key Points:

• Trump’s executive order cancels Medicare’s investigation into potential drug cost reduction strategies, including a proposed $2 monthly out-of-pocket cap on certain generic medications, signaling a shift in healthcare cost management priorities.
• The order preserves significant Inflation Reduction Act provisions, maintaining Medicare drug price negotiations, the $35 monthly insulin cost cap, and the $2,000 annual out-of-pocket prescription drug spending limit.
• Key medications like Ozempic and Wegovy remain on Medicare’s negotiation list, potentially affecting pricing structures for diabetes and weight management treatments.
• The executive order eliminates a 12-week extension for uninsured adults to enroll in healthcare coverage across 36 states, directly impacting patient access to healthcare services.
• State-level Medicaid support faces reduction through the cancellation of increased outreach funding, potentially affecting healthcare delivery systems and patient access at local levels.

“Right now, he seems to be nibbling on the edges.”
— Arthur Caplan, head of medical ethics at the NYU Grossman School of Medicine in New York City, reflecting the measured approach to healthcare policy changes

Business & Policy Summaries